← Browse by Condition
Medical Condition

neuro degenerative disease

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for neuro degenerative disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuro degenerative disease Clinical Trials

How many clinical trials are currently recruiting for neuro degenerative disease?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for neuro degenerative disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuro degenerative disease?
neuro degenerative disease research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuro degenerative disease clinical trial?
Eligibility criteria for neuro degenerative disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Carl Allen 1 trial
Karolinska Institutet 1 trial
University Health Network, Toronto 1 trial

Recruiting Clinical Trials

NCT04079179 Phase 2
Recruiting
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Enrollment
90 pts
Location
United States
Sponsor
Carl Allen
View Trial →
NCT07624630
Recruiting
Walking and Thinking - Brain Activity During Complex Walking in Stroke
Enrollment
50 pts
Location
Sweden
Sponsor
Karolinska Institutet
View Trial →
NCT03153670
Recruiting
3T MRI in Patients With Deep Brain Stimulation (DBS)
Enrollment
250 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →

Related Conditions

langerhan s cell histiocytosis (1) juvenile xanthogranuloma (1) erdheim chester disease (1) rosai dorfman disease (1) histiocytic sarcoma (1) histiocytic disorders malignant (1) stroke (1) aging (1) gait impairment in stroke patients (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology